Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 15/20 | 0.40 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.40 |
| ▸ | MAG | P20916 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13029027 | 0.94 | CD22 (0.39) | CD22NANPMAG | |
| SCHEMBL12991357 | 0.89 | NANP (0.44) | CD22NANPMAG | |
| SCHEMBL14366095 | 0.86 | NANP (0.44) | CD22NANPMAG | |
| SCHEMBL15677307 | 0.85 | NANP (0.51) | CD22NANPMAG | |
| SCHEMBL14454528 | 0.85 | NANP (0.44) | CD22NANPMAG | |
| SCHEMBL12730475 | 0.85 | NANP (0.44) | CD22NANPMAG | |
| SCHEMBL12341443 | 0.85 | NANP (0.44) | CD22NANPMAG | |
| SCHEMBL13912421 | 0.84 | NANP (0.41) | CD22NANPMAG | |
| SCHEMBL13948883 | 0.81 | NANP (0.37) | CD22NANP | |
| SCHEMBL10018768 | 0.81 | NANP (0.37) | CD22NANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842661-B2 | Glycopegylated erythropoietin formulations | NOVO NORDISK A/S (DK) | 2010-11-30 | — | — | US | disclosed |
| US-20100210507-A9 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2010-08-19 | — | — | US | disclosed |
| US-20100081791-A1 | GLYCOPEGYLATED FACTOR IX | NOVO NORDISK A/S (DK) | 2010-04-01 | — | — | US | disclosed |
| US-20100075375-A1 | METHODS FOR THE PURIFICATION OF POLYPEPTIDE CONJUGATES | NOVO NORDISK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| US-20080253992-A1 | Using hydrophobic interaction chromatography to recover therapeutic fusion protein for use in treatment of injuries associated with ischemia, trauma, inflammation and contact with toxic substances | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080176790-A1 | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) | 89BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176790-A1 | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) | FGF2, FGF1, FGFR1 | CD22 392/4885NANP 163/4885MAG 711/4885 |
| US-20100210507-A9 | Glycopegylated erythropoietin | EPOR, UGGT1, GNE | CD22 290/4885NANP 864/4885MAG 265/4885 |
| US-20100081791-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | CD22 390/4885NANP 156/4885MAG 194/4885 |
| US-20100075375-A1 | METHODS FOR THE PURIFICATION OF POLYPEPTIDE CONJUGATES | PTMS, SIGLEC7, NGLY1 | CD22 166/4885NANP 338/4885MAG 274/4885 |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | UGGT1, PTMS, GALNT1 | CD22 210/4885NANP 832/4885MAG 802/4885 |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | CSF3R, GMFG, GALNT1 | CD22 203/4885NANP 701/4885MAG 228/4885 |
| US-20080253992-A1 | Using hydrophobic interaction chromatography to recover therapeutic fusion protein for use in treatment of injuries associated with ischemia, trauma, inflammation and contact with toxic substances | PIGS, CD40, FGB | CD22 909/4885NANP 2305/4885MAG 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.